Adc Therapeutics SA (NYSE: ADCT)’s stock price has plunge by -2.17relation to previous closing price of 2.76. Nevertheless, the company has seen a -10.89% plunge in its stock price over the last five trading sessions. prnewswire.com reported 2025-06-16 that Updated Phase 2 data evaluating ZYNLONTA® as a monotherapy demonstrate overall response rate (ORR) of 85% and complete response (CR) rate of 69% CR maintained in 17 of 18 patients who achieved CR, with longest duration of CR of 27 months from start of treatment ZYNLONTA was generally well tolerated and safety was consistent with known profile LAUSANNE, Switzerland, June 16, 2025 /PRNewswire/ — ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced updated data from a Phase 2 multicenter investigator-initiated trial (IIT) of ZYNLONTA® to treat relapsed/refractory marginal zone lymphoma (r/r MZL) will be presented during a poster session at the 18th International Conference on Malignant Lymphoma (ICML) in Lugano, Switzerland on Friday, June 20. These data will be made available online beginning on Wednesday, June 18, at 8:30 a.m.
Is It Worth Investing in Adc Therapeutics SA (NYSE: ADCT) Right Now?
Additionally, the 36-month beta value for ADCT is 1.94. There are mixed opinions on the stock, with 4 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for ADCT is 77.65M and currently, short sellers hold a 5.83% ratio of that float. The average trading volume of ADCT on June 27, 2025 was 609.04K shares.
ADCT’s Market Performance
ADCT’s stock has seen a -10.89% decrease for the week, with a 8.00% rise in the past month and a 70.89% gain in the past quarter. The volatility ratio for the week is 9.61%, and the volatility levels for the past 30 days are at 11.72% for Adc Therapeutics SA The simple moving average for the past 20 days is -16.74% for ADCT’s stock, with a 21.79% simple moving average for the past 200 days.
Analysts’ Opinion of ADCT
Many brokerage firms have already submitted their reports for ADCT stocks, with Stephens repeating the rating for ADCT by listing it as a “Overweight.” The predicted price for ADCT in the upcoming period, according to Stephens is $6 based on the research report published on November 08, 2024 of the previous year 2024.
Guggenheim gave a rating of “Buy” to ADCT, setting the target price at $11 in the report published on March 28th of the previous year.
ADCT Trading at 19.56% from the 50-Day Moving Average
After a stumble in the market that brought ADCT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -34.62% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ADCT starting from Redmile Group, LLC, who purchase 100,000 shares at the price of $3.04 back on Dec 11 ’24. After this action, Redmile Group, LLC now owns 15,666,731 shares of Adc Therapeutics SA, valued at $304,500 using the latest closing price.
Redmile Group, LLC, the 10% Owner of Adc Therapeutics SA, purchase 100,000 shares at $3.04 during a trade that took place back on Dec 11 ’24, which means that Redmile Group, LLC is holding 13,145,712 shares at $304,500 based on the most recent closing price.
Stock Fundamentals for ADCT
Current profitability levels for the company are sitting at:
- -1.79 for the present operating margin
- 0.91 for the gross margin
The net margin for Adc Therapeutics SA stands at -2.13. The total capital return value is set at -0.58.
Based on Adc Therapeutics SA (ADCT), the company’s capital structure generated 3.47 points at debt to capital in total, while cash flow to debt ratio is standing at -0.4. The debt to equity ratio resting at -1.4. The interest coverage ratio of the stock is -4.92.
Currently, EBITDA for the company is -103.71 million with net debt to EBITDA at -1.41. When we switch over and look at the enterprise to sales, we see a ratio of 5.81. The receivables turnover for the company is 2.21for trailing twelve months and the total asset turnover is 0.26. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.46.
Conclusion
In conclusion, Adc Therapeutics SA (ADCT) has seen better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
